The People's Insurance Company (Group) of China Limited
The People's Insurance Company (Group) of China Limited (PINXY) Financial Performance & Income Statement Overview
Explore the financials of The People's Insurance Company (Group) of China Limited (PINXY), including yearly and quarterly data on income, cash flow, and balance sheets.
The People's Insurance Company (Group) of China Limited (PINXY) Income Statement & Financial Overview
View the income breakdown for The People's Insurance Company (Group) of China Limited PINXY across both annual and quarterly reports.
| Metric | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $153.97B | $149.45B | $126.72B | $124.88B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $153.97B | $149.45B | $126.72B | $124.88B |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $1.00 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | -$2.97B | $12.55B | $1.28B | $5.29B |
| Operating Expenses | -$1.49B | $13.91B | $7.09B | -$122.55B |
| Total Costs & Expenses | -$132.42B | -$130.88B | -$114.48B | $120.73B |
| Interest Income | $0.00 | $13.55B | $7.20B | $20.91B |
| Interest Expense | $727.00M | $739.00M | $835.00M | $1.12B |
| Depreciation & Amortization | -$194.00M | $1.19B | -$14.65B | $1.22B |
| EBITDA | $21.36B | $19.80B | -$2.37B | $2.30B |
| EBITDA Ratio | $0.14 | $0.13 | -$0.02 | $0.02 |
| Operating Income | $21.56B | -$1.43B | $14.65B | $2.33B |
| Operating Income Ratio | $0.14 | -$0.010 | $0.12 | $0.02 |
| Other Income/Expenses (Net) | -$921.00M | -$3.25B | -$2.40B | $4.14B |
| Income Before Tax | $20.64B | $17.88B | $11.44B | $4.14B |
| Income Before Tax Ratio | $0.13 | $0.12 | $0.09 | $0.03 |
| Income Tax Expense | $5.95B | $2.73B | $1.79B | $270.00M |
| Net Income | $13.64B | $13.72B | $8.96B | $2.27B |
| Net Income Ratio | $0.09 | $0.09 | $0.07 | $0.02 |
| EPS | $0.31 | $0.31 | $0.20 | $0.84 |
| Diluted EPS | $0.31 | $0.31 | $0.20 | $0.27 |
| Weighted Avg Shares Outstanding | $44.22B | $44.22B | $44.22B | $6.79B |
| Weighted Avg Shares Outstanding (Diluted) | $44.22B | $44.22B | $44.22B | $2.16B |
The company's financials show resilient growth, with revenue advancing from $124.88B in Q4 2023 to $153.97B in Q3 2024. Gross profit remained healthy with margins at 100% in Q3 2024 compared to 100% in Q4 2023. Operating income hit $21.56B last quarter, sustaining a consistent 14% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $21.36B. Net income dropped to $13.64B, while earnings per share reached $0.31. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan